Paul B. Mullan
Belfast, NIR, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications
Unbiased combination screening on repurposed drugs reveals synergistic potential of copanlisib and cerivastatin against chemoresistant high-grade serous ovarian cancer.
Journal: Journal of ovarian research
Published: June 24, 2025
A SRC-slug-TGFβ2 signaling axis drives poor outcomes in triple-negative breast cancers.
Journal: Cell communication and signaling : CCS
Published: April 08, 2024
A bespoke target selection tool to guide biomarker discovery in tubo-ovarian cancer.
Journal: Computational and structural biotechnology journal
Published: March 05, 2022
TBX2 acts as a potent transcriptional silencer of tumour suppressor genes through interaction with the CoREST complex to sustain the proliferation of breast cancers.
Journal: Nucleic acids research
Published: July 20, 2021
Sympathetic cooling of positrons to cryogenic temperatures for antihydrogen production.
Journal: Nature communications
Published: April 21, 2021
USP17 is required for peripheral trafficking of lysosomes.
Journal: EMBO reports
Published: October 20, 2020
Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer.
Journal: Cancers
Published: August 17, 2020
Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes.
Journal: World journal of clinical oncology
Published: March 29, 2020
Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast Cancer.
Journal: Journal of oncology
Published: January 30, 2020
Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer.
Journal: Therapeutic advances in medical oncology
Published: September 16, 2019
Defining the molecular evolution of extrauterine high grade serous carcinoma.
Journal: Gynecologic oncology
Published: May 01, 2019
Fibroblast-derived Gremlin1 localises to epithelial cells at the base of the intestinal crypt.
Journal: Oncotarget
Published: February 25, 2019
Last Updated: 09/26/2026